Corbus Pharmaceuticals Holdings, Inc.

CRBP Nasdaq SEC CIK 1595097
Follow Corbus Pharmaceuticals Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$35M −98.4% vs same quarter last year
EPS, diluted −$1.81 −25.7% vs same quarter last year
Operating cash flow −$29.6M −78.5% vs same quarter last year
Operating income −$36.2M −89% vs same quarter last year
Net income by quarter
−$13.8M
−$9.5M
−$17M
−$17.7M
−$23.3M
−$20.6M
−$23M
−$35M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$78.5M
FY24-−$40.2M
FY23-−$44.6M
FY22$0−$42.3M
FY21$881.7K−$45.6M
FY20$3.9M−$111.3M
FY19$36.1M−$71.5M
FY18$4.8M−$55.7M
FY17$2.4M−$32.4M
FY16$1.9M−$20M
FY15$648.4K−$8.9M
FY14-−$2.5M
FY13-−$602.4K
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21−6350.1%−5176.4%
FY20−3119.2%−2826.1%
FY19−213.3%−197.7%
FY18−1176.8%−1154.5%
FY17−1334.4%−1328.6%
FY16−1045.6%−1046.3%
FY15−1365.5%−1365.1%
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$64.5M
FY24−$41.8M
FY23−$36.1M
FY22−$37.6M
FY21−$48.2M
FY20−$100.2M
FY19−$48.5M
FY18−$32.4M
FY17−$28.5M
FY16−$13.9M
FY15−$4.7M
FY14−$2.4M
FY13-
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Corbus Pharmaceuticals
  • Healthcare median
−6000%−4000%−2000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCorbus PharmaceuticalsHealthcare median
FY25-−40.6%
FY24-−60.7%
FY23-−97.1%
FY22-−128.5%
FY21−5176.4%−129.2%
FY20−2826.1%−136.5%
FY19−197.7%−133.7%
FY18−1154.5%−173.4%
FY17−1328.6%−176.7%
FY16−1046.3%−164.8%
FY15−1365.1%−183.4%
FY14-−133%
FY13-−88.5%
FY12-−87.4%

News

No stories filed under Corbus Pharmaceuticals yet - coverage appears here as the news feed clusters it.